Trends and Key Areas of Research in the Pathophysiology, Imaging, and Treatment of Type 3 Macular Neovascularization (MNV3) Associated with Age-Related Macular Degeneration (AMD) - Scorecard - MDSpire
Advertisement
Trends and Key Areas of Research in the Pathophysiology, Imaging, and Treatment of Type 3 Macular Neovascularization (MNV3) Associated with Age-Related Macular Degeneration (AMD)
Clinical Scorecard: Trends and Key Areas of Research in the Pathophysiology, Imaging, and Treatment of Type 3 Macular Neovascularization (MNV3) Associated with Age-Related Macular Degeneration (AMD)
At a Glance
Category
Detail
Condition
Type 3 Macular Neovascularization (MNV3) associated with Age-Related Macular Degeneration (AMD)
Key Mechanisms
Retinal-derived neovascular lesion originating from the retinal deep capillary plexus, penetrating the RPE layer.
Target Population
Patients with wet AMD, specifically those with MNV3.
Care Setting
Ophthalmology clinics and research institutions.
Key Highlights
MNV3 is strongly associated with reticular pseudodrusen and has a predictable progression to macular atrophy.
Anti-VEGF therapy is the first-line treatment but has limited efficacy due to disease heterogeneity.
Emerging research focuses on multi-targeted therapeutic options and the use of artificial intelligence for diagnosis.
Guideline-Based Recommendations
Diagnosis
Utilize optical coherence tomography (OCT) for early identification of MNV3.
Management
Implement standardized therapeutic regimens for MNV3, primarily using anti-VEGF agents.
Monitoring & Follow-up
Regular imaging evaluations to assess progression and treatment response.
Risks
Monitor for complications such as macular atrophy associated with anti-VEGF therapy.
Patient & Prescribing Data
Individuals diagnosed with wet AMD, particularly those exhibiting MNV3.
Efficacy of anti-VEGF therapy may vary; consider multi-targeted approaches.
Clinical Best Practices
Conduct thorough risk stratification for patients with MNV3.
Stay updated on emerging research and treatment modalities in MNV3 management.
Supplying ocular nutritional supplements (ONS) is a way to deepen patient trust and improve their visual outcomes, with the byproduct a new revenue stream. This is the theme of this issue of Optometric Management.
Terry Kim, MD, discusses his roles as CMO and head of global medical safety at Alcon, why and how he moved in this direction with his career, the Unity Vitreoretinal Cataract and Unity Cataract Systems, and more.
The combination of photodynamic therapy and intravitreal aflibercept did not improve 1-year visual acuity outcomes compared with aflibercept monotherapy.
